Capricor Therapeutics Inc Share Price Nasdaq
Equities
US14070B1017
Biotechnology & Medical Research
Sales 2024 * | 21.4M 1.71B | Sales 2025 * | 89.52M 7.13B | Capitalization | 167M 13.31B |
---|---|---|---|---|---|
Net income 2024 * | -33M -2.63B | Net income 2025 * | 8M 638M | EV / Sales 2024 * | 7.8 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.87 x |
P/E ratio 2024 * |
-5.49
x | P/E ratio 2025 * |
54.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.66% |
Latest transcript on Capricor Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 19/11/13 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 19/11/13 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 20/07/23 |
Earl Collier
BRD | Director/Board Member | 76 | 19/11/13 |
George Dunbar
BRD | Director/Board Member | 77 | 19/11/13 |
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+0.20% | 22.25B | |
-13.14% | 22.09B | |
-7.80% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |